English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Treatment choices and neuropsychological symptoms of a large cohort of early MS

MPS-Authors
/persons/resource/persons80578

Weber,  Frank
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;
External Organizations;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

NEURIMMINFL2017015206.pdf
(Publisher version), 295KB

Supplementary Material (public)
There is no public supplementary material available
Citation

von Bismarck, O., Dankowski, T., Ambrosius, B., Hessler, N., Antony, G., Ziegler, A., et al. (2018). Treatment choices and neuropsychological symptoms of a large cohort of early MS. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 5(3): e446. doi:10.1212/NXI.0000000000000446.


Cite as: https://hdl.handle.net/21.11116/0000-0002-8996-A
Abstract
Objective
To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.
Methods
The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.
Results
Of 1,124 patients, with a 2.2: 1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.
Conclusion
Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.